SLI's asset financing model, proven across other asset classes, such as transportation and energy, now accelerates deployment of orbital infrastructure

PASADENA, Calif., Sept. 14, 2026 /PRNewswire/ -- Sophia Space today announced a $300 million financing framework with aerospace leasing specialist, SLI, for a planned 10-satellite high-performance edge computing constellation, bringing proven financing models used to scale aviation, energy, maritime, rail, and telecommunications, into this next phase of orbital computing. Under the arrangement, SLI will purchase the satellites from Sophia and lease them to the end-users on the basis of fixed monthly or quarterly payments.

Once deployed, the constellation would deliver aggregate computing capacity equivalent to 240 state-of-the-art edge servers, while allowing Sophia to preserve equity capital for technology development and operations.

The collaboration also reflects a long-term commitment between the two companies to develop the financing structures and deployment playbook that orbital compute infrastructure will require to move from the laboratory to low Earth orbit.

"Asset financing didn't invent aviation or shipping, but it accelerated them at scale," said Rob DeMillo, CEO and Cofounder of Sophia Space. "We're doing the same for orbital computing. This approach with SLI signals that Sophia Space's space infrastructure is mature enough to attract the capital structures that have historically built terrestrial infrastructure."

The financing structure, outlined in a non-binding letter of support, aligns SLI's financing with Sophia's build and deployment schedule, supporting the purchase and deployment of 10 Sophia TILE spacecraft through a long-term operating lease. Mission launches are scheduled for as early as 2028.

The constellation is designed to deliver in-orbit edge data services for applications including Earth observation, weather analytics, supply-chain management, and disaster preparedness, while also addressing growing demand for intelligence, surveillance, and reconnaissance (ISR) and other mission-critical security applications.

"Lowering barriers to entry unlocks markets," explained Praveen Vetrivel, Chief Executive Officer at SLI. "Sophia has the technology, the team, and the vision. What had been missing was access to scalable, non-dilutive capital. This framework provides it, giving them the capacity and flexibility they need to build the next layer of digital infrastructure."

The long-term lease is designed to span the satellites' expected useful lives, matching capital deployment with the revenue-generating life of the assets. The approach provides Sophia with a predictable financing structure for scaling its orbital infrastructure without relying exclusively on equity capital.

SLI is the aerospace subsidiary of Libra Group, which brings more than $15 billion in asset financing experience in the transportation industries to the space economy.

About Sophia Space Inc.

Sophia Space is building the future of orbital computing and in-space data centers. Its modular TILE technology enables passive computing alongside in-situ data processing, AI acceleration, and edge computing for satellites, defense systems, and commercial space stations, dramatically reducing latency and delivering actionable insights where and when they are needed. Learn more at www.sophia.space

About SLI

SLI was established by Libra Group in 2023 to address the capital needs of the rapidly growing aerospace industry by providing flexible, innovative asset-financing solutions with an initial focus on satellites, ground stations and frontier aviation assets, such as zero-emission electric aircraft. Leveraging Libra Group companies' decades of experience owning and leasing high-value, mission-critical assets around the world across aviation, maritime, and renewable energy, SLI seeks to bridge the gap between capital availability and asset deployment, accelerating the creation of an integrated aerospace economy. www.sliaerospace.com

SOURCE Sophia Space

Share this article

'Travel China with the Spring Festival Gala' new season captivates audiences with fresh take on urban cultural tourism

YIBIN, China, Sept. 13, 2026 /PRNewswire/ -- "Travel China with the Spring Festival Gala" invites viewers to step into mountains and seas and discover that each city holds a thousand years of history. It is an urban cultural tourism reality show heavily invested in by China Media Group, and its new 2026 season is currently airing. With Spring Festival Gala branch venue cities as its coordinates, the show transforms each city's geographical texture, cultural heritage and modern development into accessible and engaging variety content through live-action competitive games and immersive cultural exploration, making "traveling with the Spring Festival Gala" a new paradigm for cultural tourism integration.

The first stop, Yiwu, showcased the open vitality of the "world's supermarket" through cross-cultural interaction and received widespread praise from audiences. The following chapter, Yibin, built on the unique status of "the first city on the Yangtze River," integrating the three cultural genes of tea, liquor and bamboo with contemporary themes such as new energy and ecological governance. The entire city became a moving live-action arena, translating Yibin's landscape, culture and industrial ambitions into lighthearted variety language. Audiences can see the cultural lineage in the charm of tea, liquor and bamboo, feel the city's new vitality in Yibin's smart manufacturing including power batteries, and understand, amid laughter, the enterprising pulse of this river city as it inherits the past and inspires the future.

"Travel China with the Spring Festival Gala" comes from the Spring Festival Gala stage, transforming one-way city introductions into flowing, two-way co-creation. Rooted in the Spring Festival Gala IP, it has made a city popular and allowed more people to see China's diverse charm. Stay tuned for the next stop and more discoveries.

SOURCE Travel China with the Spring Festival Gala

Share this article

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chinese as "关爱计划-延伸" of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), with Blau syndrome as the proposed indication. The relevant public notice period ended on September 11, 2026. Previously, in June 2026, the U.S. Food and Drug Administration (FDA) granted AC-101 Rare Pediatric Disease (RPD) designation for the treatment of Blau syndrome (BS).

About AC-101

AC-101 is a novel, selective RIPK2 inhibitor derived from Accro Bioscience's proprietary drug discovery platform targeting regulatory cell death and inflammation. It is being developed for the treatment of moderate-to-severe ulcerative colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD/RIPK2 signaling is associated with multiple inflammatory and autoimmune diseases, including inflammatory bowel disease (IBD). AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The efficacy and safety results from this study will be presented at UEG Week 2026. For details, please see the related press release.

About Blau Syndrome

Blau syndrome is a rare hereditary autoinflammatory disease caused by pathogenic variants in the NOD2 gene. It usually begins in early childhood and can involve multiple systems, including the skin, joints and eyes. Its classic clinical presentation is the triad of granulomatous dermatitis, arthritis and uveitis. Joint involvement may lead to joint deformity and functional impairment over time. Ocular involvement can cause uveitis; if not controlled promptly, it may lead to severe visual impairment or even blindness.[1,2]

About Accro Bioscience

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company's robust pipeline of first- and best-in-class compounds offers the potential to bring innovative, paradigm-shifting therapies to patients.

For more information, please visit www.accropeutics.com.

[1]. NIH/NLM MedlinePlus Genetics — Blau syndrome

[2]. NIH/NLM MeSH — Blau syndrome

SOURCE Accro Bioscience (Suzhou) Limited

Share this article

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as

a Target in Second- or Later-Line EGFR NSCLC

Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed

ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place September 12-15, 2026, in Seoul, Republic of Korea.

In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care (SoC) treatments, including chemotherapy and immunotherapy, and demonstrated less treatment associated variation than several other ADC targets in late-stage development. PTK7 expression was also generally consistent regardless of the presence or absence of other actionable genomic alterations (AGA). These findings indicate PTK7 remains available for targeted ADCs for patients that have progressed through multiple lines of SoC therapy and across clinically relevant subgroups.

A separate analysis of patients with advanced EGFR wild-type lung adenocarcinoma found that real-world overall survival was not impacted based on PTK7-expression, supporting PTK7 as a target-engagement biomarker for ADC payload delivery independent of prognosis in NSCLC.

"The development strategy for our PTK7-directed ADC, HWK-007, is grounded in understanding not only where PTK7 is expressed, but also how that expression behaves in a real-world treatment setting," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "The stability of PTK7 expression after standard of care therapies, in particular compared to other therapies in late-stage development, add important translational context as we evaluate HWK-007 in patients with EGFR wild-type NSCLC."

Key Findings:

Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

- PTK7 expression remained largely stable following standard-of-care immunotherapy, chemotherapy, chemoimmunotherapy and tyrosine kinase inhibitor treatment, suggesting that the target may remain available for PTK7-directed therapy after prior treatment.

- Stable PTK7 expression is also observed in paired tumor samples.

- PTK7 demonstrated less treatment-associated variation than several late-stage ADC targets, including MET, PD-L1 and ITGB6.

- PTK7 expression was generally consistent across tumors with or without other AGA, including KRAS G12C, ALK and MET alterations, suggesting relevance of PTK7 as an ADC target across both AGA+ and AGA- NSCLC subgroups.

Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma

- PTK7 expression was not independently associated with real-world overall survival or progression-free survival in patients with advanced EGFR wild-type lung adenocarcinoma receiving second- or later-line therapy, supporting PTK7 as a target-engagement biomarker rather than a marker of prognosis.

- Clinical outcomes were driven primarily by established prognostic factors, including Eastern Cooperative Oncology Group performance status and extent of prior therapy.

- PTK7-low tumors were enriched for KEAP1 and STK11 alterations, suggesting biological heterogeneity of EGFR wild-type NSCLC.

"Understanding whether a therapeutic target remains present after prior treatment is particularly important in advanced lung cancer, where patients often receive multiple lines of therapy," said Aaron E. Lisberg, MD, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA. "The stability of PTK7 expression across standard treatments and clinically relevant molecular subgroups supports further investigation of PTK7-directed ADCs in patients with previously treated EGFR wild-type lung adenocarcinoma."

Poster Presentation Details:

Title: Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

Poster: P2.241

Presenter: Aaron E. Lisberg, MD, University of California Los Angeles, Los Angeles, CA, USA

Date & Time: Monday, September 14, 2026, at 10:30 AM KST

Title: Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma

Poster: P2.147

Presenter: Grace Dy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Date & Time: Monday, September 14, 2026, at 10:30 AM KST

HWK‑007 is PTK7-directed, next-generation ADC being evaluated in an ongoing Phase 1 clinical trial in patients with non-squamous, EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer (NCT07444814).

These analyses were conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.

About Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to the potential therapeutic value and market opportunity for HWK-007 and  expectations regarding the beneficial characteristics, design features and the potential targeted markets with respect to HWK-007. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of HWK-007 .

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

[email protected]

SOURCE Whitehawk Therapeutics, Inc.

Share this article

- RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET

- Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%

SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone. The combination extended median OS by more than six months, despite 76 percent of eligible patients in the chemotherapy arm crossing over to second-line RYBREVANT after disease progression. This represents the longest reported median OS in this patient population, which is nearly twice the historical median.1

These results were presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Late-breaking Abstract #PL.03.03).

Resetting survival expectations for patients with historically poor outcomes

EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations.2 Unlike more common EGFR mutations (exon 19 deletions and L858R), exon 20 insertion mutations have been difficult to treat with targeted medicines, leaving patients with few treatment options, challenging side effects and poorer outcomes.3 Historically, median overall survival has ranged from approximately 16 to 24 months, with five-year survival reported at just eight percent.4,5,6

RYBREVANT is a first-in-class bispecific antibody designed to dual-target EGFR and mesenchymal-epithelial transition (MET), two key drivers of tumor growth and treatment resistance, while also engaging the immune system.7,8,9,10 It is currently approved for use in patients with EGFR-mutated advanced NSCLC across common (exon 19 deletions and exon 21 L858R substitution mutations) and exon 20 insertion mutations, in the first- and second-line settings.11

Expert and company perspectives on longer survival in historically difficult-to-treat lung cancer

"We've come a long way in treating EGFR exon 20 insertion-positive lung cancer, and these results demonstrate the lasting impact RYBREVANT plus chemotherapy can have in helping patients live longer," said Dr. Chul Kim, M.D., M.P.H.,* Director of Thoracic Oncology, MedStar Georgetown University Hospital. "Patients are continuing treatment years after they started, which speaks to the durability of this approach and its value as a first-line treatment for this disease."

"We have long believed RYBREVANT could transform the outlook for patients with EGFR-mutated lung cancer by addressing key drivers of disease progression and treatment resistance," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "With the longest survival seen in this patient population, these results add to the growing body of evidence across common, atypical and exon 20 insertion EGFR mutations and further establish the regimen as a backbone therapy."

Detailed overall survival results

In the protocol-specified final analysis, RYBREVANT plus chemotherapy demonstrated a median OS of nearly three years (34.3 months) compared to approximately two years (27.9 months) for chemotherapy alone (hazard ratio [HR], 0.87; 95 percent confidence interval [CI], 0.66-1.14; P=0.307). A prespecified analysis accounting for crossover to RYBREVANT in the chemotherapy arm showed a significant overall survival benefit with RYBREVANT plus chemotherapy, reducing the risk of death by 43 percent (HR, 0.57; 95 percent CI, 0.39-0.82; nominal P=0.003).1

Long-term follow-up provides further evidence of durable benefit, with RYBREVANT plus chemotherapy extending progression-free survival through second disease progression (PFS2) by more than 10 months compared with chemotherapy alone (28.3 vs. 17.5 months; HR, 0.59; 95 percent CI, 0.45-0.77; nominal P0.0001). Twelve percent of patients remained on first-line treatment at the clinical cutoff compared with no patients in the chemotherapy arm. Patient-reported outcomes also favored the combination, delaying the worsening of several key lung cancer symptoms compared with chemotherapy alone.1

The safety profile of IV RYBREVANT plus chemotherapy was consistent with previous reports from studies conducted before prophylactic strategies were introduced, with no new safety signals observed with longer follow-up. The most common treatment-related adverse events occurring in at least 30 percent of patients included paronychia (60 percent), neutropenia (60 percent) and rash (58 percent).1

These overall survival findings build on the primary PAPILLON analysis, which demonstrated a statistically significant and clinically meaningful 60 percent improvement in progression-free survival (primary endpoint) with first-line RYBREVANT plus chemotherapy versus chemotherapy alone in patients with EGFR exon 20 insertion mutation-positive advanced NSCLC. Clinical benefit in the primary analysis was consistent across key patient subgroups, including patients with brain metastases, EGFR exon 20 insertion variants and TP53 co-mutations. Those results, which supported global approvals of the regimen in this setting, were simultaneously published in The New England Journal of Medicine.12

Additional data presented at WCLC 2026 highlight continued innovation across RYBREVANT and RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), with approaches aimed at improving the treatment experience and helping patients stay on treatment longer. This includes prophylactic strategies in the COPERNICUS study (Abstract #MO12.09) designed to reduce key treatment-related events and subcutaneous administration evaluated in the PALOMA-2 study (Abstract #PT2.03.06).

About the PAPILLON study

PAPILLON (NCT04538664), which enrolled 308 patients, is a randomized, open-label Phase 3 study evaluating the efficacy and safety of RYBREVANT in combination with chemotherapy, compared with chemotherapy alone, in newly diagnosed patients with advanced or metastatic non-small cell lung cancer characterized by EGFR exon 20 insertion mutations. The primary endpoint of the study is progression-free survival (PFS) (using RECIST v1.1 guidelines†) as assessed by blinded independent central review (BICR). Secondary endpoints include overall response rate (ORR), PFS after first subsequent therapy, time to symptomatic progression and overall survival. Patients who received chemotherapy alone were allowed to receive RYBREVANT monotherapy in the second-line setting after confirmation of disease progression.

Patients randomized to chemotherapy alone were permitted to cross over to receive second-line RYBREVANT monotherapy after disease progression confirmed by BICR, reflecting the study's crossover design for patients in the control arm.13

About non-small cell lung cancer

Worldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) making up 80 to 85 percent of all lung cancer cases.14,15 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.16 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.17 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.14,15,18,19,20,21 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.22 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.23,24 EGFR exon 20 insertion mutations are the third-most prevalent activating EGFR mutation.2 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.25

About RYBREVANT FASPRO and RYBREVANT

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved for these EGFR-mutated NSCLC populations and may be used as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy, depending on the specific mutation and treatment setting. For eligible patients, RYBREVANT FASPRO offers a once-monthly dosing option following initial weekly dosing. RYBREVANT FASPRO is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT FASPRO is approved in the U.S. for the same indications as intravenous RYBREVANT (amivantamab-vmjw) across multiple markets. RYBREVANT is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.

The effectiveness of RYBREVANT FASPRO is supported by the established clinical profile of RYBREVANT, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE in first-line advanced EGFR-mutated NSCLC.

Shanghai Electric Secures First Overseas Heavy-Duty Gas Turbine Order for 500 MW Malaysian Project

SHANGHAI, Sept. 13, 2026 /PRNewswire/ -- Shanghai Electric (SEHK: 02727, SSE: 601727) has achieved a milestone in the high-end overseas energy sector by securing the contract for Unit 3 of the Sarawak Samalaju Combined Cycle Gas Turbine (CCGT) Project in Malaysia. The win represents significant international recognition of Shanghai Electric's heavy-duty gas turbine technology, underscoring the company's growing competitiveness in the global gas turbine market.

Under the agreement, Shanghai Electric will deliver a full EPC turnkey solution for the gas-fired power plant, coupled with a 25-year long-term service agreement (LTSA) covering all major equipment. Notably, every core component—from gas turbines and steam turbines to generators, heat recovery steam generators, and air-cooled systems—will be manufactured in-house by Shanghai Electric, which will also serve as the sole provider of the long-term maintenance and service program. This integrated, end-to-end capability gives Shanghai Electric full life-cycle coverage, spanning equipment manufacturing, systems integration, and multi-decade operational support—a vertical model that brings the company on par with the established global leaders in the heavy-duty gas turbine sector.

Shanghai Electric's current heavy-duty gas turbine lineup features two principal models, with output ratings of 300 MW and 78 MW, respectively. To date, the company has delivered 103 units, with total installed capacity from commissioned projects exceeding 21,000 MW. The units covered by Shanghai Electric's long-term service and maintenance programs have accumulated more than 1.3 million operating hours. With robust production capacity available across both turbine classes, Shanghai Electric is positioned to offer new units for delivery as early as 2028. Beyond the Malaysian energy developer that awarded the current contract, project developers in Indonesia, Thailand, the Philippines, and Vietnam have also expressed strong interest in placing orders.

SOURCE Shanghai Electric

Share this article

Franco-Nevada Announces A$200 Million Follow-on Financing Package with Minerals 260 for the Bullabulling Gold Project

(in U.S. dollars unless otherwise noted)

TORONTO, Sept. 13, 2026 /PRNewswire/ -- Franco-Nevada Corporation ("Franco-Nevada" or the "Company") (TSX:FNV) (NYSE:FNV) is pleased to announce that, through a wholly-owned Australian subsidiary, it has entered into an agreement to acquire a A$170 million (approximately $122 million) gross royalty (the "Royalty") from Minerals 260 Limited ("Minerals 260") to further support its development of the Bullabulling Gold Project ("Bullabulling" or the "Project"). Additionally, Franco-Nevada has agreed to subscribe for A$30 million (approximately $22 million) of Minerals 260's ordinary shares (the "Shares") as a lead order in a future equity raise.

The Royalty acquisition will be in addition to Franco-Nevada's Australian subsidiary's existing 2.45% gross royalty interest over the Project, increasing its interest to a 3.90% gross royalty over Bullabulling, plus an expanded area of interest and enhanced Royalty profile. The investment in Minerals 260 Shares will build upon Franco-Nevada's existing ownership of Minerals 260 Shares.

This financing package increases Franco-Nevada's support for Minerals 260 to develop Bullabulling to an aggregate A$420 million (approximately $300 million) and follows the A$220 million (approximately $155 million) financing package that Franco-Nevada provided Minerals 260 in February 2026 which has supported considerable resource growth and development progress at Bullabulling and significant appreciation of Minerals 260's Share price since this time.

Paul Brink, President & CEO of Franco-Nevada said: "Both the team at Minerals 260 and the Bullabulling orebody continue to surpass our expectations. Minerals 260 is ahead of schedule on project development and financing and has rapidly grown its resource endowment. We are delighted to take this next step in building our partnership with the company and firmly believe that our financial backing can play a lynchpin role in generating value for Minerals 260 shareholders."

Luke McFadyen, Managing Director of Minerals 260, commented: "We are thrilled with the partnership we have established with Franco-Nevada and Franco-Nevada's decision to invest an additional A$200 million supports what both parties believe Bullabulling will become - a near-term, large scale, long-life, expandable gold asset in one of the world's best mining jurisdictions. This is a partnership built on focus and determination to bring Bullabulling into production and supports mutually beneficial outcomes for each company. This additional funding materially strengthens our balance sheet and our path to final investment decision in early 2027."

Transaction Highlights

- Near-Term Production Pathway: Bullabulling is one of Australia's largest near-term gold projects, located approximately 65 km from Kalgoorlie, Western Australia in the Eastern Goldfields, with a recently upgraded Resource in July 2026 of 4.4 Moz Indicated Resources (140 Mt at 0.98 g/t) and 1.7 Moz Inferred Resources (51 Mt at 1.0 g/t). The Project is located on existing mining leases and has a straightforward pathway to meaningful near-term production from conventional open-pit and CIL processing. A pre-feasibility study was completed by Minerals 260 in July 2026, with a definitive feasibility study and final investment decision expected in early 2027, and first gold production potentially as soon as H2 2028.

- Meaningful Production Profile: Minerals 260's intended strategy is to incrementally develop and expand Bullabulling to accelerate and optimize production. The pre-feasibility study was based on the maiden reserve (reflecting resources as of December 2025) and Stage 1 throughput of 5 Mtpa, with additional capacity and design provisions incorporated to support future throughput expansion to 7.5 Mtpa. The pre-feasibility study confirmed Franco-Nevada's assessment that Bullabulling will be a scaled, long life mine, with planned annual average gold production of approximately 150 koz per annum for the first 10 years and total mine life of 19 years. Based on Franco-Nevada's review and current Resources, we see strong potential for throughput expanding in phases to 7 to 8 Mtpa, which corresponds with historical studies and Minerals 260's indicative development plan indicating Stage 2 production of 200 koz per annum.1

- Substantial Funding for Project Development: Royalty financing proceeds, together with additional proceeds from a future Minerals 260's equity raise, are expected to fully fund the equity component required to bring Bullabulling into production and will enable Minerals 260 to maintain the project development momentum at Bullabulling through to a definitive feasibility study and a final investment decision expected in early 2027.

- Large Mineral Resource with Exploration Potential: The Royalty covers a large Resource base, including the Phoenix, Bacchus, Dicksons, and Kraken deposits, which cover 8.5 km strike-length on the Bullabulling trend and the Gibraltar deposit which currently spans 1 km strike-length on a sub-parallel trend. Since acquiring the Project in 2025, Minerals 260 has had success growing the Resource through the first significant drilling campaign on the Project since 2011, nearly tripling Mineral Resources. Considerable growth potential continues to exist on the deposits both along strike and at depth, along with conversion of Inferred Resources. We expect the financing proceeds will assist Minerals 260 to continue expanding their Resource base through both exploration and infill drilling on ground covered by the Royalty, along with bringing the Project into production.

- Expanded Area of Interest and Enhanced Royalty Profile: The area of interest for the Royalty surrounding the boundary of the existing Royalty tenure will expand from 2.5 km to 10 km, resulting in the Royalty capturing additional mineral trend extensions and covering a total area of approximately 650 km2. In addition, the Royalty step down production threshold, based upon gold produced from Royalty lands, will increase from 4 Moz to 6 Moz of gold, providing enhanced duration and optionality for the Royalty as resources and production from Bullabulling grow.

- Continued Partnership with Experienced Board & Management Team: Minerals 260 is led by its Chairman Tim Goyder, who has over 40 years of experience in the resource industry and is Minerals 260's second largest shareholder. Mr. Goyder is also the Chairman of Liontown Limited which recently developed and is operating the Kathleen Valley Lithium mine in Western Australia. The Minerals 260 management team is led by its Chief Executive Officer and Managing Director, Luke McFadyen who has over 15 years of mining industry experience and, prior to joining Minerals 260 in 2023, held senior roles at OZ Minerals, Syrah Resources, South32 and BHP.

Key Terms

Royalty Acquisition

- Upfront proceeds of A$170 million (approximately $122 million) for an additional 1.45% gross royalty over the Royalty area so that Franco-Nevada's Australian subsidiary will hold an effective 3.90% gross royalty over Bullabulling, with payment upon closing

- Upon production of 6 Moz of gold from Royalty lands, the Royalty will step down from 3.90% to 2.75%

- The area of interest for the Royalty will be 10 km from the boundary of historical Royalty tenure

- Franco-Nevada's Australian subsidiary will maintain a right of first refusal on future streams, royalties and similar interests related to the Royalty properties

Equity Participation

- Franco-Nevada has committed to provide an incremental cornerstone investment of A$30 million (approximately $22 million), as a lead order in a future equity financing

Financing the Transactions

Franco-Nevada intends to finance the transactions from cash on hand. The Company had $1.0B in cash and $4.3B in available capital as at June 30, 2026.

Franco-Nevada Corporate Summary

Franco-Nevada Corporation is the leading gold-focused royalty and streaming company with the largest and most diversified portfolio of cash-flow producing assets. Its business model provides investors with gold price and exploration optionality while limiting exposure to cost inflation. Franco-Nevada is debt-free and uses its free cash flow to expand its portfolio and pay dividends. It trades under the symbol FNV on both the Toronto and New York stock exchanges. Franco-Nevada is the gold investment that works.

About Minerals 260

Minerals 260 is building an Australian gold company by developing the Bullabulling Gold Project, located approximately 65 km from Kalgoorlie, Western Australia in the Eastern Goldfields. Minerals 260's shares are listed on the Australian Securities Exchange (ASX:MI6). For more information, visit www.minerals260.com.au.

Additional Information

Minerals 260's head office is located at Level 1, 2 Kings Park Road, West Perth WA 6005. Franco-Nevada's head and registered office is located at 2000-199 Bay Street, Commerce Court West, Toronto, Ontario, M5L 1G9. Information relating to Bullabulling contained in this news release has been provided by Minerals 260. All Mineral Resource estimates are reported by Minerals 260 in accordance with the JORC Code (2012).

Scientific and technical information included in this news release has been reviewed by Darrol van Deventer, Vice President, Mining of Franco-Nevada, a qualified person under National Instrument 43-101.

IonOpticks launches Aurora Series® 5 and new CoreJet™ emitter technology, advancing robust nano-LC for routine proteomics research.

New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in robustness, lowering cost per sample without compromising the depth and sensitivity researchers depend on.

MELBOURNE, Australia, Sept. 13, 2026 /PRNewswire/ -- IonOpticks, the world's leading manufacturer of high-performance chromatography solutions for LC-MS-based proteomics, today announces the release of Aurora Series 5: the most significant robustness upgrade in the platform's history. In extended testing on a Thermo Scientific Vanquish Neo UHPLC coupled to an Orbitrap Astral Zoom mass spectrometer, Series 5 sustained over 10,000 unique protein identifications across more than 1,000 injections on an 8-minute, 120-samples-per-day method, with no climb in backpressure beyond 1,400 runs. The result: nanoflow-level depth and sensitivity that laboratories can now run as a routine, high-throughput workflow rather than reserve for landmark experiments.

At the centre of the upgrade are two platform-wide technology developments: CoreJet integrated emitter technology and a redesigned nanoZero union. Together, they deliver more consistent backpressure, improved spray stability and greater reliability over prolonged use without trading away the performance that has established Aurora Series as a benchmark for deep and sensitive proteomics.

"Aurora Series has built its reputation on depth of coverage, sensitivity and reproducibility, but researchers increasingly need exceptional performance they can rely on every day," says Xavier Perronnet, Chief Executive Officer at IonOpticks. "With Series 5, we have combined that performance with a new level of robustness, giving laboratories the confidence to use these columns routinely across demanding workflows. This is the most significant upgrade we have made to Aurora Series, and an important step towards making exceptional chromatography the everyday standard rather than something reserved for occasional use."

CoreJet technology introduces a completely redesigned architecture for the integrated pulled emitter, a feature that has always been fundamental to the product. The high-performance CoreJet emitter is fully integrated into the analytical column, ensuring true-zero dead volume post-column and eliminating the concealed unions between column and emitter that create dead-volumes, degrade chromatographic performance and reduce analyte discovery. This new architecture is engineered to deliver substantially greater robustness, improving resistance to early clogging and overpressure events, extending column longevity and supporting prolonged use across increasingly complex sample series.

"True robustness is about more than how long a column lasts. It is about continuing to deliver the depth of coverage, sensitivity and throughput researchers expect, despite the variable and demanding conditions of everyday laboratory use," says Dr. Jarrod Sandow, Chief Product Officer at IonOpticks. "Across extended testing, Aurora Series 5 maintained its chromatographic performance through more than 1,400 injections. For researchers running everything from individual experiments to large sample cohorts, that means greater confidence that the chromatography will perform consistently, day after day."

Series 5 also introduces a redesigned nanoZero union, providing a more reliable voltage connection to the liquid passing through the column. Ensuring consistent voltage to the analytical column is essential for stable electrospray ionisation, the process that transfers molecules leaving the column into the mass spectrometer for measurement. By creating a more dependable electrical connection, the redesigned nanoZero union supports further improved spray stability over large sample cohorts while making column setup simpler and easier.

A fundamental priority underpinning Series 5 development was ensuring the new products maintained the strong column-to-column and batch-to-batch reproducibility for which Aurora Series is known. Across all testing, coefficients of variation remain below one per cent for median protein and peptide identifications, supporting consistent performance across a column's service life and from column to column. Spray stability remains similarly consistent throughout prolonged testing across both instrument platforms. On the Thermo Scientific Vanquish Neo coupled to an Orbitrap Astral Zoom, and the Bruker nanoElute 2 coupled to a timsTOF HT, extended injection series show no spray dropouts, with consistent signal maintained throughout testing. This provides further evidence that Series 5 can sustain stable ionisation and chromatography across prolonged, high-throughput use.

For laboratories processing hundreds or even thousands of samples, the value extends beyond column lifetime alone. Greater stability means fewer unexpected interruptions and column changes, less time spent troubleshooting, more effective use of valuable mass spectrometry capacity, and greater confidence that an extended experiment can continue on a consistent chromatographic platform. This translates to a meaningful reduction in laboratory overheads and helps researchers make better use of both instrument time and research budgets.

When paired with an IonOpticks NanoShield® C18 trap column, Series 5 gains additional protection from sample-derived contamination while significantly reducing sample loading times. By protecting the analytical column from more challenging samples, NanoShield can extend Aurora Series 5 column life even further, creating a workflow that combines speed, lossless protection and high-performance chromatography with an even more compelling value proposition than established market alternatives.

Aurora Series 5 represents a shift in what laboratories can expect from high-performance nanoflow chromatography. The depth and sensitivity remain, but they are now delivered through a platform designed to withstand the demands of everyday proteomics, whether that means a landmark discovery experiment, a large-scale cohort, or the hundreds of routine injections in between.

As Series 5 replaces Aurora Series 4, IonOpticks will retain limited Series 4 stock during the transition period to support continuity for existing customers and ongoing studies. Aurora Series 5 with CoreJet integrated emitter technology is available across the range from 15 September 2026, directly from IonOpticks and through its global distribution network.

About IonOpticks

IonOpticks is a global leader in high-performance chromatography solutions, empowering the research community to push the boundaries of LC-MS and advanced proteomics. By dramatically enhancing the sensitivity and reliability of mass spectrometry, IonOpticks enables scientists and clinicians to uncover more insights from every sample. These innovations drive discovery across diverse applications, including drug development, phosphoproteomics, shotgun proteomics, and clinical research. Trusted by leading laboratories worldwide, IonOpticks combines cutting-edge technology with a commitment to advancing biological and medical science.

For more information about IonOpticks' products and research impact, please visit www.ionopticks.com.

SOURCE IonOpticks

Share this article

CB&I AND AG&P INDUSTRIAL ACHIEVE FIRST-OF-ITS-KIND MILESTONE WITH ALL-STEEL FULL CONTAINMENT LNG TANKS IN THE PHILIPPINES

THE WOODLANDS, Texas, Sept. 13, 2026 /PRNewswire/ -- CB&I and its client AG&P Industrial have successfully completed and commissioned two 60,000m³ full containment liquefied natural gas (LNG) storage tanks at the LNGPH Ilijan LNG Facility in the Philippines, marking a significant milestone for both the project and the global LNG industry.

The project represents the first large-scale onshore LNG storage facility in the Philippines and showcases CB&I's innovative all-steel full containment LNG tank technology. Unlike conventional full containment LNG tanks that rely on reinforced concrete outer walls, the CB&I design, deployed under its agreement with AG&P Industrial, uses 9% nickel steel for both the inner and outer tanks while assuring compliance with LNG industry technical and safety standards.

The successful commissioning of Tank 1 marked the world's first in-service full containment all-steel LNG tank. With Tank 2 now also fully operational following successful performance testing, the facility stands as a proven demonstration of a technology that delivers enhanced economics, faster construction schedules, and the safety benefits of full containment LNG storage.

CB&I completed construction of the tanks with zero lost-time incidents over more than one million work hours, underscoring the project's strong safety performance.

"The successful commissioning of both tanks at Ilijan is a landmark achievement for all involved," said Jack Aughenbaugh, Vice President, Operations – International at CB&I. "This project demonstrates that all-steel full containment LNG storage is not only technically feasible but commercially advantageous, delivering safety and operational benefits of full containment storage while improving project economics and schedule certainty. We are proud to have partnered with AG&P Industrial, in support of LNGPH, to establish a new benchmark for LNG infrastructure projects in the region and beyond."

"CB&I has been an excellent partner to AG&P Industrial in delivering the first and largest world-class LNG import terminal in the Philippines on time, in a safe, reliable, and cost-effective manner," said Alexander Leo Gamboa, President & CEO of AG&P Industrial. "We will surely work with CB&I again for our future projects."

About CB&I

CB&I delivers integrated storage and asset‑management solutions that help customers operate safely, reliably, and efficiently across the lifecycle of their facilities. Through our two global business units—Storage Solutions, the world leader in tanks, terminals, and storage systems, and Asset Solutions, a leading provider of operations, management, wells and decommissioning services—we combine technical excellence with execution capability to extend asset life, optimize performance, and maximize value. CB&I is owned by a consortium of financial investors led by Mason Capital Management LLC. To learn more, visit www.cbi.com.

Forward Looking Statements

CB&I cautions that statements in this communication that are forward-looking, and provide other than historical information, involve risks, contingencies, and uncertainties. These forward-looking statements include, among other things, statements about the expected timing and execution of projects, and statements that describe our business strategy, outlook, objectives, plans, intentions, or goals. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are based on various underlying assumptions and are subject to numerous risks, contingencies, and uncertainties, many of which are beyond our control, including, among others: adverse changes in the markets in which we operate or in credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope, or timing of contracts, contract cancellations, change orders, and other modifications or actions by our customers and other business counterparties; changes in industry norms or codes or applicable laws; actions by lenders, other creditors, customers, and other business counterparties of CB&I; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materializes, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of CB&I's management as of the date hereof. Except to the extent required by applicable law, CB&I undertakes no obligation to update or revise any forward-looking statement.

SOURCE CB&I STS Delaware LLC

Share this article

100 participants took to 100 reformers to celebrate Pilates' centennial and BODYBAR's 100th studio opening

FORT WORTH, Texas, Sept. 13, 2026 /PRNewswire/ -- BODYBAR Pilates, a leading modern Pilates franchise, today announced it successfully completed the largest reformer Pilates class on record in the United States. The first-of-its-kind workout brought together 100 participants on 100 reformers in Frisco, Texas. Held on Sunday, September 13, the event commemorated both the 100th anniversary of Pilates and BODYBAR's milestone 100th studio opening. The event also raised $10,000, $100 per reformer, for the Foundation for Women's Cancer in recognition of September's Gynecological Cancer Awareness Month, helping further the organization's mission to support and empower all affected by gynecologic cancers through education, research, and public awareness.

The 50-minute class took place during the brand's annual conference at the Omni Frisco Hotel at The Star and featured BODYBAR's franchise owners and instructors nationwide, along with invited media. The class was led by certified BODYBAR Pilates instructor and BODYBAR's Chief Brand Officer, President and Co-Founder, Kamille McCollum, alongside a team of BODYBAR instructors.

"We wanted to celebrate Pilates' centennial and our 100th studio opening in a fun, meaningful way, and this event exceeded every expectation," said Kamille McCollum. "Bringing together 100 participants on 100 reformers was an incredible and unforgettable celebration of the power of Pilates. Plus, having our team members, franchise owners and instructors all participate made it even more special. This event is a testament to how far both Pilates and BODYBAR have come and the incredible fitness communities built along the way. Cheers to 100 more years!"

The record-setting event comes just days after another major milestone for the Texas-founded brand. On Tuesday, September 8, BODYBAR opened its 100th studio in Presidio in North Fort Worth, in the very market where the franchise began. The milestone marks a significant moment in the brand's growth as it continues expanding its footprint nationwide.

In 1926, Joseph and Clara Pilates opened their first Pilates studio in New York City. One hundred years later, BODYBAR Pilates did its part to honor the anniversary by bringing together 100 reformers and 100 participants moving as one.

The class was made possible by Balanced Body®, Inc., the global leader in the design and manufacturing of Pilates equipment and education, which provided all 100 reformers. Additional partners included McCollister's, handling shipping, setup and installation of the reformers; Pilabarre, the official grip sock sponsor for the class; FitRadio, providing on-site entertainment featuring resident DJ Stacie Hawk Carroll; and TAVI, gifting participants custom monogrammed "100" grip socks.

The event was independently organized and documented using standards consistent with formal record-keeping organizations. Verification materials, including participant counts, photographs and video documentation, have been compiled and are available upon request.

To find a studio, book a first class or learn more, visit BODYBARPilates.com or check out the brand on Instagram, Facebook or YouTube. To learn more about available franchising opportunities, visit BODYBARPilates.com/Franchise.

About BODYBAR Pilates

Founded to redefine fitness, BODYBAR Pilates' mission is to cultivate a balanced, athletic, and real community. We are committed to providing a fiercely effective workout experience, powered by Pilates, that helps individuals discover their physical potential and enhance their overall well-being both on and off the reformer. Our expert-led classes cater to all fitness levels in a welcoming environment, utilizing state-of-the-art Pilates equipment. As a growing franchise, BODYBAR presents an exciting opportunity for entrepreneurs in the fitness industry. Joining the BODYBAR family means becoming part of a movement that empowers individuals to achieve their fitness goals while building a thriving, community-centric business. This opportunity is ideal for entrepreneurs looking to make a meaningful impact in the fitness world with a reputable, innovative brand.

About The Foundation for Women's Cancer

The Foundation for Women's Cancer (FWC) is dedicated to increasing public awareness of gynecologic cancer risk, prevention, early detection, and optimal treatment. As the official foundation of the Society of Gynecologic Oncology (SGO), FWC is a 501 (c)(3) nonprofit organization that provides funding for gynecologic cancer research and training, as well as programs and resources. FWC has raised more than $60 million in areas such as research, awareness, education, and outreach. For more information, visit https://www.foundationforwomenscancer.org.

MEDIA CONTACT:

Alexis Paul

Tidehouse

954-893-9150

[email protected]

SOURCE BODYBAR Pilates

Share this article